Market Pulse Breaking News Alert for Thursday, May 12, 2005: MTNU - Martin Nutraceuticals Is Pleased to Announce the Effects of Oxygenol(TM) on Chronic Fatigue and Fibromyalgia!

Market Pulse News Alert for this AM, Stocks to Watch are: Martin Nutraceuticals, Inc. (OTC: MTNU), Google Inc. (NASDAQ: GOOG), Cisco Systems Inc. (NASDAQ: CSCO), and Medical Staffing Solutions Inc. (OTC BB: MSSI).

Investors need to be watching Martin Nutraceuticals, Inc. (OTC: MTNU) this AM! Martin Nutraceuticals is a company focused on developing natural and alternative medicine products that provide better health for individuals through the use of their wide range of products. The flagship product which is based on Joint Therapy is used to aid in joint and general arthritic pain. Over $3.9 billion is spent on over-the-counter and prescription medication for arthritis, joint and muscle related pain in North America alone! Dr. Martin's products have amassed sales of over $35 million! MTNU had great news out before today's opening bell announcing Dr. Martin concurs that Oxygenol's efficacy is what makes it a fantastic product, one that we anticipate will prosper in a market that does more than $1 billion in annual sales! Investors should be watching this one closely!

MMartin Nutraceuticals Inc.'s (OTC: MTNU) Director of Research and Development, Dr. A. W. Martin, is pleased to announce results of recent clinical trials of Oxygenol in the aid of Chronic Fatigue Syndrome and Fibromyalgia.

Oxygenol is a proprietary blend of antioxidants with many health benefits. In the study, Oxygenol was given to patients suffering from Chronic Fatigue Syndrome and Fibromyalgia. These two conditions are characterized by extreme fatigue and cognitive symptoms which include sleep disorder, short term memory loss, concentration difficulties, widespread musculoskeletal aches, pain and stiffness and soft tissue tenderness.

Dr. Martin states, ``Fibromyalgia is a symptom of the greater complex of Chronic Fatigue Syndrome -- one that perhaps should be considered a sister ailment."

The test patients were given 200 mg daily of Oxygenol in a 6-week period. In this amount of time, over 3/4 of the patients showed that 85% of all cognitive symptoms were decreased and remarkably 1/4 of these cases showed over 95% improvement of all cognitive symptoms with the use of Martin Nutraceuticals Oxygenol. The tests that were used included Short Term Memory Testing using recall and concentration, as well as Cognitive Testing.

Dr. Martin attributes these findings to Oxygenol's ability to cross the blood brain barrier and increase micro circulation to the brain. "Oxygenol's efficacy is what makes it a fantastic product, one that we anticipate will prosper in a market that does more than $1 billion in annual sales," concurs Dr. Martin.

Dr. Martin is a Canadian nutritional researcher and author of several books including ``Chronic Fatigue Syndrome: the Modern Women's Curse."

Martin Nutraceuticals' Oxygenol will be available in exclusive retail outlets by the third quarter of this year.

Stocks acting well as of late include: Google Inc. (NASDAQ: GOOG), Cisco Systems Inc. (NASDAQ: CSCO), and Medical Staffing Solutions Inc. (OTC BB: MSSI).

Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated in free trading shares of common stock, available for public trading as follows: Martin Nutraceuticals, Inc. compensation from a third party: four hundred thousand free trading shares of stock in Martin Nutraceuticals, Inc., already delivered from a third party. To date, MP has sold forty two thousand three hundred shares of stock in Martin Nutraceuticals, Inc. for proceeds totaling twenty four thousand six hundred dollars. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. Market Pulse News Alert is a division of MP.